ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last2,641 to 2,660 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
FF/VI 100 mcg/25 mcg vs Usual Care: Number of Participants With Serious Adverse Events (SAEs) of Pneumonia During the Study94 of 1,396

83 of 1,403

0.8 points

-1.0 to 2.6

2,799NCT01551758

A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)

FF/VI 100 mcg/25 mcg vs Usual Care: Time to First Moderate/Severe Exacerbations Occurring in a Year947 of 1,396

977 of 1,403

-1.8 points

-5.2 to 1.6

2,799NCT01551758

A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)

FF/VI 100 mcg/25 mcg vs Usual Care: Time to the Addition of a Further COPD Controller Medication Occurring in a Year72 of 1,396

142 of 1,403

-5.0 points

-6.9 to -3.0

2,799NCT01551758

A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)

FF/VI 100 mcg/25 mcg vs Usual Care: Time to First Severe Exacerbations Occurring in a Year122 of 1,396

97 of 1,403

1.8 points

-0.2 to 3.8

2,799NCT01551758

A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)

FF/VI 100 mcg/25 mcg vs Usual Care: Number of Participants With Serious Adverse Drug Reactions23 of 1,396

10 of 1,403

0.9 points

0.1 to 1.8

2,799NCT01551758

A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)

FF/VI 100 mcg/25 mcg vs Usual Care: Number of Participants With Serious Adverse Events404 of 1,396

383 of 1,403

1.6 points

-1.7 to 5.0

2,799NCT01551758

A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)

FF/VI 100 mcg/25 mcg vs Usual Care: Number of Participants With Fatal Serious Adverse Events of Pneumonia13 of 1,396

13 of 1,403

0.0 points

-0.8 to 0.8

2,799NCT01551758

A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)

FF/VI 100 mcg/25 mcg vs Usual Care: serious adverse events404 of 1,396

383 of 1,403

1.6 points

-1.7 to 5.0

2,799NCT01551758

A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)

Investigational Vaccine vs Control Group: serious adverse events257 of 1,399

258 of 1,396

-0.1 points

-3.0 to 2.8

2,795NCT00953927

A Study of MVA85A in Healthy Infants

Intensive Blood-Pressure Lowering vs Guideline-Recommended Blood-Pressure Lowering: A Composite of Death or Dependency, With Dependency Being Defined by a Score of 3 to 5 on the Modified Rankin Scale (mRS)719 of 1,382

785 of 1,412

-3.6 points

-7.3 to 0.1

2,794NCT00716079

The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial

Investigational Vaccine vs Control Group: To Evaluate the QuantiFERON Conversion Rate at Final Study Assessment in MVA85A/AERAS-485 Recipients Compared to Controls in Infants Without a Diagnosis of Tuberculosis During the Trial.178 of 1,398

171 of 1,394

0.5 points

-2.0 to 2.9

2,792NCT00953927

A Study of MVA85A in Healthy Infants

V419 Lots A, B, and C Combined vs Control: serious adverse events94 of 2,390

15 of 397

0.2 points

-2.3 to 1.9

2,787NCT01340937

A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)

Intervention Group vs Control Group: Number of Patients With Abnormal Laboratory Results Received and Recognized by Provider1,339 of 1,426

1,292 of 1,357

-1.3 points

-3.0 to 0.4

2,783NCT02798354

Reducing Diagnostic Errors in Primary Care Pediatrics (Project RedDE)

Intervention Group vs Control Group: Number of Patients With Abnormal Laboratory Results With Appropriate Actions Without Delay1,329 of 1,426

1,273 of 1,357

-0.6 points

-2.5 to 1.2

2,783NCT02798354

Reducing Diagnostic Errors in Primary Care Pediatrics (Project RedDE)

Nintedanib Initiators Cohort vs Pirfenidone Initiators Cohort: Number of Patients With Dose Reduction and/or Temporary Dose Reduction (Sub-optimal Dose) by 12 Months301 of 1,389

373 of 1,389

-5.2 points

-8.4 to -2.0

2,778NCT05779007

Dose Reduction and Discontinuation With Anti-Fibrotic Medications

Group 1: MenACYW Conjugate Vaccine vs MENVEO®: Number of Participants With Medically Attended Adverse Event (MAAEs)1,581 of 2,080

526 of 697

0.5 points

-3.0 to 4.3

2,777NCT03673462

Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Group 1: MenACYW Conjugate Vaccine vs Group 2: MENVEO®: Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs)7 of 2,080

2 of 697

0.0 points

-0.7 to 0.5

2,777NCT03673462

Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Group 1: MenACYW Conjugate Vaccine vs Group 2: MENVEO®: deaths from any cause3 of 2,080

0 of 697

0.1 points

-0.4 to 0.4

2,777NCT03673462

Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Group 1: MenACYW Conjugate Vaccine vs Group 2: MENVEO®: Number of Participants With Unsolicited Adverse Events1,352 of 2,080

437 of 697

2.3 points

-1.8 to 6.5

2,777NCT03673462

Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Group 1: MenACYW Conjugate Vaccine vs Group 2: MENVEO®: serious adverse events108 of 2,080

21 of 697

2.2 points

0.4 to 3.6

2,777NCT03673462

Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=133"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=133

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT01551758-8119a972",
        "title": "FF/VI 100 mcg/25 mcg vs Usual Care: Number of Participants With Serious Adverse Events (SAEs) of Pneumonia During the Study",
        "summary": "94 of 1396 against 83 of 1403; risk difference 0.8 points, 95% interval -1.0 to 2.6; NCT01551758, A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)",
        "record": "/library/comparisons/NCT01551758-8119a972",
        "nct_id": "NCT01551758",
        "kind": "outcome",
        "participants": 2799,
        "risk_difference": {
          "value": 0.008176298435403469,
          "lower": -0.009949845672234989,
          "upper": 0.02638393685750703
        },
        "group_1": "94 of 1,396",
        "group_2": "83 of 1,403",
        "difference": "0.8 points",
        "interval": "-1.0 to 2.6",
        "trial_title": "A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)"
      },
      {
        "id": "NCT01551758-c8ea559f",
        "title": "FF/VI 100 mcg/25 mcg vs Usual Care: Time to First Moderate/Severe Exacerbations Occurring in a Year",
        "summary": "947 of 1396 against 977 of 1403; risk difference -1.8 points, 95% interval -5.2 to 1.6; NCT01551758, A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)",
        "record": "/library/comparisons/NCT01551758-c8ea559f",
        "nct_id": "NCT01551758",
        "kind": "outcome",
        "participants": 2799,
        "risk_difference": {
          "value": -0.017998170110303913,
          "lower": -0.05228135682213559,
          "upper": 0.01633790053643234
        },
        "group_1": "947 of 1,396",
        "group_2": "977 of 1,403",
        "difference": "-1.8 points",
        "interval": "-5.2 to 1.6",
        "trial_title": "A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=134",
  "request_id": "fQU1YI7KJbPJ2LqF"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?